Percutaneous Coracohumeral Release for Patients with Adhesive Capsulitis: Two-Year Results from a Randomized Control Crossover Study.

IF 2.6 2区 医学 Q2 ANESTHESIOLOGY
Pain physician Pub Date : 2024-07-01
Ugur Yener, Tahereh Naeimi, Alan D Kaye, Konrad Izumi Gruson, Sandeep Yerra, Jonathan Alerte, David Gonzalez, Pramod Badu Voleti, Eloy Tabeayo Alvarez, Sayed Emal Wahezi
{"title":"Percutaneous Coracohumeral Release for Patients with Adhesive Capsulitis: Two-Year Results from a Randomized Control Crossover Study.","authors":"Ugur Yener, Tahereh Naeimi, Alan D Kaye, Konrad Izumi Gruson, Sandeep Yerra, Jonathan Alerte, David Gonzalez, Pramod Badu Voleti, Eloy Tabeayo Alvarez, Sayed Emal Wahezi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adhesive capsulitis (AC) causes a variety of symptoms, including but not limited to pain, stiffness, and a gradual restriction of active and passive range of motion (ROM). The coracohumeral ligament (CHL) plays an important role in this disease process, and percutaneous CHL release (PCHLR) has demonstrated efficacy in treating manifestations of this disorder that are refractory to pain medication, physical therapy, and local injections. Our previous study demonstrated one-year efficacy and durability, and this study examines 2-year data from our original randomized control crossover cohort.</p><p><strong>Objective: </strong>To highlight the importance of extended follow-ups evaluating PCHLR's efficacy in AC management.</p><p><strong>Study design: </strong>A prospective, randomized, controlled, cross-over trial.</p><p><strong>Setting: </strong>An academic medical center.</p><p><strong>Methods: </strong>Patients with AC refractory to oral medication, physiotherapy, and at least one local injection were included in our original study. In all, there were initially 40 patients (46 shoulders), including 6 patients who underwent bilateral PCHLR using the Tenex® system. In this prospective study, 2 groups, the experiment group (scheduled to receive PCHLR) and the control group (scheduled to receive a local anesthetic in the coracohumeral ligament [LACHL]) were determined through 2-to-1 block randomization. Of these 46 shoulders initially treated, 39 remained in the study at one year. Twenty-six of the 39 shoulders were assigned to the PCHLR group whereas 13 were assigned to the LACHL group. Nine out of 13 shoulders in the LACHL group crossed over to the PCHLR group. Ultimately, 31 shoulders remained in the PCHLR group for 2-year analysis. The effectiveness of these interventions was assessed using a variety of parameters. Pain scores, ROM, and the Oxford Shoulder Score (OSS) were evaluated before the procedure and at one-year and 2-year follow-up visits.</p><p><strong>Results: </strong>In this 2-year follow-up study, a total of 31 shoulders were sampled, comprising 22 women and 5 men, with 4 patients undergoing bilateral procedures. The mean age of the patients was 65 years (± 11.48). Patients' mean body mass index (BMI) was 36.33 (± 6.55), and the mean CHL thickness was 38.5 (± 3.45). Osteoarthritis was present in 11 cases. The mean follow-up period for the study was 29.7 months (± 6.39). The baseline mean external rotation was 30° (± 8), which increased to 62° (± 18) at one year and 53° (± 18) at 2 years. The baseline mean abduction was 60° (± 16), which improved to 77° (± 21) at one year and 68° (± 20) at 2 years. The median NRS decreased from 8 (IQR: 8, 9) at baseline to 3 (IQR: 2, 7) at one year and 5 (IQR: 2, 7) at 2 years. The baseline median OSS was 7 (IQR: 3, 10), which increased to 32 at one year and 22 (IQR: 15, 35) at 2 years.</p><p><strong>Limitations: </strong>The present investigation has a limited sample size of patients who have ROM impairment caused by CHL thickening.</p><p><strong>Conclusions: </strong>While the algorithm for AC care has seen little change for several decades, the authors suggest that PCHLR is a safe, durable, and effective option for cases of AC that are refractory to traditional management.</p>","PeriodicalId":19841,"journal":{"name":"Pain physician","volume":"27 5","pages":"303-307"},"PeriodicalIF":2.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain physician","FirstCategoryId":"3","ListUrlMain":"","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Adhesive capsulitis (AC) causes a variety of symptoms, including but not limited to pain, stiffness, and a gradual restriction of active and passive range of motion (ROM). The coracohumeral ligament (CHL) plays an important role in this disease process, and percutaneous CHL release (PCHLR) has demonstrated efficacy in treating manifestations of this disorder that are refractory to pain medication, physical therapy, and local injections. Our previous study demonstrated one-year efficacy and durability, and this study examines 2-year data from our original randomized control crossover cohort.

Objective: To highlight the importance of extended follow-ups evaluating PCHLR's efficacy in AC management.

Study design: A prospective, randomized, controlled, cross-over trial.

Setting: An academic medical center.

Methods: Patients with AC refractory to oral medication, physiotherapy, and at least one local injection were included in our original study. In all, there were initially 40 patients (46 shoulders), including 6 patients who underwent bilateral PCHLR using the Tenex® system. In this prospective study, 2 groups, the experiment group (scheduled to receive PCHLR) and the control group (scheduled to receive a local anesthetic in the coracohumeral ligament [LACHL]) were determined through 2-to-1 block randomization. Of these 46 shoulders initially treated, 39 remained in the study at one year. Twenty-six of the 39 shoulders were assigned to the PCHLR group whereas 13 were assigned to the LACHL group. Nine out of 13 shoulders in the LACHL group crossed over to the PCHLR group. Ultimately, 31 shoulders remained in the PCHLR group for 2-year analysis. The effectiveness of these interventions was assessed using a variety of parameters. Pain scores, ROM, and the Oxford Shoulder Score (OSS) were evaluated before the procedure and at one-year and 2-year follow-up visits.

Results: In this 2-year follow-up study, a total of 31 shoulders were sampled, comprising 22 women and 5 men, with 4 patients undergoing bilateral procedures. The mean age of the patients was 65 years (± 11.48). Patients' mean body mass index (BMI) was 36.33 (± 6.55), and the mean CHL thickness was 38.5 (± 3.45). Osteoarthritis was present in 11 cases. The mean follow-up period for the study was 29.7 months (± 6.39). The baseline mean external rotation was 30° (± 8), which increased to 62° (± 18) at one year and 53° (± 18) at 2 years. The baseline mean abduction was 60° (± 16), which improved to 77° (± 21) at one year and 68° (± 20) at 2 years. The median NRS decreased from 8 (IQR: 8, 9) at baseline to 3 (IQR: 2, 7) at one year and 5 (IQR: 2, 7) at 2 years. The baseline median OSS was 7 (IQR: 3, 10), which increased to 32 at one year and 22 (IQR: 15, 35) at 2 years.

Limitations: The present investigation has a limited sample size of patients who have ROM impairment caused by CHL thickening.

Conclusions: While the algorithm for AC care has seen little change for several decades, the authors suggest that PCHLR is a safe, durable, and effective option for cases of AC that are refractory to traditional management.

粘连性囊炎患者的经皮肱骨角膜松解术:一项随机对照交叉研究的两年结果。
背景:粘连性关节囊炎(AC)会导致多种症状,包括但不限于疼痛、僵硬以及主动和被动活动范围(ROM)逐渐受限。肱骨冠状韧带(CHL)在这一疾病过程中起着重要作用,经皮肱骨冠状韧带松解术(PCHLR)已证明能有效治疗止痛药、理疗和局部注射难治性疾病。我们之前的研究显示了一年的疗效和持久性,本研究对我们最初的随机对照交叉队列的两年数据进行了检查:研究设计:研究设计:前瞻性、随机对照、交叉试验:地点:一家学术医疗中心:我们最初的研究纳入了口服药物、物理治疗和至少一次局部注射治疗无效的急性前列腺炎患者。最初共有 40 名患者(46 个肩膀),其中 6 名患者使用 Tenex® 系统接受了双侧 PCHLR。在这项前瞻性研究中,通过 2 对 1 的随机分组,确定了两组,即实验组(计划接受 PCHLR)和对照组(计划接受冠状肱韧带 [LACHL] 局麻药)。在最初接受治疗的 46 个肩部中,有 39 个在一年后仍留在研究中。39 个肩部中有 26 个被分配到 PCHLR 组,13 个被分配到 LACHL 组。LACHL 组的 13 个肩关节中有 9 个转到了 PCHLR 组。最终,PCHLR 组中仍有 31 个肩关节接受了为期 2 年的分析。这些干预措施的有效性通过各种参数进行评估。在手术前以及一年和两年的随访中,对疼痛评分、关节活动度和牛津肩关节评分(OSS)进行了评估:在这项为期两年的随访研究中,共采集了 31 例肩关节样本,其中女性 22 例,男性 5 例,4 例患者接受了双侧手术。患者的平均年龄为 65 岁(± 11.48)。患者的平均体重指数(BMI)为 36.33(± 6.55),平均 CHL 厚度为 38.5(± 3.45)。11例患者患有骨关节炎。研究的平均随访时间为 29.7 个月(± 6.39)。基线平均外旋角度为30°(± 8),一年后增至62°(± 18),两年后增至53°(± 18)。基线平均外展角度为 60°(± 16),一年后增至 77°(± 21),两年后增至 68°(± 20)。NRS的中位数从基线时的8(IQR:8,9)下降到一年时的3(IQR:2,7)和两年时的5(IQR:2,7)。基线OSS中位数为7(IQR:3,10),一年后增至32,两年后增至22(IQR:15,35):局限性:本次调查的样本量有限,仅限于因CHL增厚导致ROM受损的患者:作者认为,对于传统治疗无效的 AC 病例,PCHLR 是一种安全、持久、有效的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pain physician
Pain physician CLINICAL NEUROLOGY-CLINICAL NEUROLOGY
CiteScore
6.00
自引率
21.60%
发文量
234
期刊介绍: Pain Physician Journal is the official publication of the American Society of Interventional Pain Physicians (ASIPP). The open access journal is published 6 times a year. Pain Physician Journal is a peer-reviewed, multi-disciplinary, open access journal written by and directed to an audience of interventional pain physicians, clinicians and basic scientists with an interest in interventional pain management and pain medicine. Pain Physician Journal presents the latest studies, research, and information vital to those in the emerging specialty of interventional pain management – and critical to the people they serve.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信